The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Open accessAbstract
IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
In the citing paper
“The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 95,97 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [97]
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [122]
In the citing paper
“These observations support a model in which PU.1 guides TET2 to a specific subset of genomic regions to facilitate the oxidation of 5mC to 5hmC, a reaction that is inhibited by 2-hydroxyglutarate47 and enhanced by vitamin C13 (Figure 5d).”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [47]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“HIF-1a is a transcription factor whose function is linked to metabolism, angiogenesis and tumorigenesis, and whose protein level is downregulated under normoxic conditions by PHD-mediated hydroxylation and subsequent hydroxylation-targeted ubiquitination (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2…”
Self-citationEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Flagged first, then by citations
1 of the 55 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Han, 2007, Structural basis for histone demethylation by JHDM1, Frontier Science, 1, 52
Cited by
Sorted by citations
Items 401–500 of 1,006
Andronesi, O. C., Arrillaga‐Romany, I., Ly, I., Bogner, W., Ratai, E., Reitz, K., Iafrate, A. J., Dietrich, J., Gerstner, E. R., Chi, A. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03905-6 · Cited by 141
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Yu, D., Liu, Y., Zhou, Y., Ruiz‐Rodado, V., Larion, M., Xu, G., & Yang, C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913633117 · Cited by 142
Self-citationKadiyala, P., Carney, S. V., Gauss, J. C., Garcia-Fabiani, M. B., Haase, S., Alghamri, M. S., Núñez, F. J., Liu, Y., Yu, M., Taher, A. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139542 · Cited by 143
Self-citationMethylation across the central dogma in health and diseases: new therapeutic strategies
Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 155
DNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Breathing-in epigenetic change with vitamin C
Monfort, A., & Wutz, A. (2013) · The EMBO Reports · doi:10.1038/embor.2013.29 · Cited by 140
Non-invasive in vivo assessment of IDH1 mutational status in glioma
Chaumeil, M. M., Larson, P. E. Z., Yoshihara, H. A. I., Danforth, O. M., Vigneron, D. B., Nelson, S. J., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2013) · Nature Communications · doi:10.1038/ncomms3429 · Cited by 142
Salminen, A., Kauppinen, A., Hiltunen, M. O., & Kaarniranta, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.05.004 · Cited by 145
Deng, G., Shen, J., Yin, M., McManus, J., Mathieu, M., Gee, P., He, T., Shi, C., Bedel, O., McLean, L. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608497 · Cited by 138
Self-citationAsmar, F., Punj, V., Christensen, J. F., Pedersen, M. T., Pedersen, A., Nielsen, A. B., Hother, C. E., Ralfkiær, U., Brown, P. D. N., Ralfkiaer, E. M., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.088740 · Cited by 147
Morandi, A., Taddei, M. L., Chiarugi, P., & Giannoni, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00040 · Cited by 146
Critical Enzymatic Functions of FTO in Obesity and Cancer
Deng, X., Su, R. J., Stanford, S., & Chen, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00396 · Cited by 143
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 145
Control of endothelial quiescence by FOXO-regulated metabolites
Andrade, J., Shi, C., Costa, A. S. H., Choi, J., Kim, J., Doddaballapur, A., Sugino, T., Ong, Y. T., Castro, M., Zimmermann, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00637-6 · Cited by 133
Zhao, A., Zhou, H., Yang, J., Li, M., & Niu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01342-6 · Cited by 153
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Self-citationTET Enzymes and 5hmC in Adaptive and Innate Immune Systems
Lio, C. J., & Rao, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00210 · Cited by 144
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
Bastien, J., McNeill, K. A., & Fine, H. A. (2014) · Cancer · doi:10.1002/cncr.28968 · Cited by 146
Youssef, G., & Miller, J. J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01040-8 · Cited by 144
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 140
Self-citationmTORC2 in the center of cancer metabolic reprogramming
Masui, K., Cavenee, W. K., & Mischel, P. S. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.04.002 · Cited by 140
The role of epigenetics in the biology of multiple myeloma
Dimopoulos, K., Gimsing, P., & Grønbæk, K. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.29 · Cited by 133
Chen, J.-Y., Li, C., Kuo, C.-C., Tsai, K. K., Hou, M., & Hung, W.-C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0410-1 · Cited by 145
Advances in histone demethylase KDM4 as cancer therapeutic targets
Lee, D. H., Kim, G. W., Jeon, Y. H., Yoo, J. H., Lee, S. W., & Kwon, S. H. (2020) · The FASEB Journal · doi:10.1096/fj.201902584r · Cited by 137
Bauer, C., Göbel, K., Nagaraj, N., Colantuoni, C., Wang, M., Müller, U., Kremmer, E., Rottach, A., & Leonhardt, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.605881 · Cited by 144
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Chiang, S., Weigelt, B., Wen, H., Pareja, F. G., Raghavendra, A., Martelotto, L. G., Burke, K. A., Basili, T., Li, A., Geyer, F. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0298 · Cited by 137
Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?
Ficz, G., & Gribben, J. G. (2014) · Genomics · doi:10.1016/j.ygeno.2014.08.017 · Cited by 135
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Stuani, L., Sabatier, M., Wang, F., Poupin, N., Bosc, C., Saland, E., Castelli, F. A., Gales, L., Montersino, C., Boët, E., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200924 · Cited by 143
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Shi, D. D., Savani, M. R., Levitt, M. M., Wang, A. C., Endress, J. E., Bird, C. E., Buehler, J., Stopka, S. A., Regan, M. S., Lin, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.011 · Cited by 140
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Molecular pathogenesis of IDH mutations in gliomas
Ichimura, K. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0090-4 · Cited by 134
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 134
Genomic insights into cancer-associated aberrant CpG island hypermethylation
Sproul, D., & Meehan, R. R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els063 · Cited by 135
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 135
Tseng, C.-W., Kuo, W., Chan, S., Chan, H., Chang, K., & Wang, L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2906 · Cited by 131
The function and regulation of TET2 in innate immunity and inflammation
Cong, B., Zhang, Q., & Cao, X. (2020) · Protein & Cell · doi:10.1007/s13238-020-00796-6 · Cited by 135
T cell exhaustion in malignant gliomas
Watowich, M., Gilbert, M. R., & Larion, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2022.12.008 · Cited by 140
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
Zhang, C., Moore, L. M., Li, X., Yung, W. K. A., & Zhang, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not087 · Cited by 136
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 133
The chemistries and consequences of DNA and RNA methylation and demethylation
Traube, F. R., & Carell, T. (2017) · RNA Biology · doi:10.1080/15476286.2017.1318241 · Cited by 131
Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer
Benjamin, D. I., Cravatt, B. F., & Nomura, D. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.013 · Cited by 131
Precancer Atlas to Drive Precision Prevention Trials
Spira, A. E., Yurgelun, M. B. B., Alexandrov, L. B., Rao, A., Bejar, R., Polyák, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2346 · Cited by 134
Vitamin C in Stem Cell Biology: Impact on Extracellular Matrix Homeostasis and Epigenetics
D’Aniello, C., Cermola, F., Patriarca, E. J., & Minchiotti, G. (2017) · Stem Cells International · doi:10.1155/2017/8936156 · Cited by 135
The Janus-like role of proline metabolism in cancer
Burke, L. E. C.-A., Guterman, I., Palacios-Gallego, R., Britton, R. G., Burschowsky, D., Tufarelli, C., & Rufini, A. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00341-8 · Cited by 131
Wang, F., Morita, K., Dinardo, C. D., Furudate, K., Tanaka, T. N., Yan, Y., Patel, K. P., MacBeth, K. J., Wu, B., Liu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22874-x · Cited by 137
Self-citationNucleic Acid Oxidation in DNA Damage Repair and Epigenetics
Zheng, G., Fu, Y., & He, C. (2014) · Chemical Reviews · doi:10.1021/cr400432d · Cited by 131
Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond
Chen, C.-W. D., & Armstrong, S. A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.012 · Cited by 126
Characterization of gliomas: from morphology to molecules
Ferris, S. P., Hofmann, J. W., Solomon, D. A., & Perry, A. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2181-4 · Cited by 130
Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation
Chisolm, D. A., & Weinmann, A. S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053127 · Cited by 133
Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma
Lechner, A., Henkel, F. D. R., Hartung, F., Bohnacker, S., Alessandrini, F., Gubernatorova, E. O., Drutskaya, M. S., Angioni, C., Schreiber, Y., Haimerl, P., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.026 · Cited by 128
Origins of aberrant DNA methylation in acute myeloid leukemia
Schoofs, T., Berdel, W. E., & Müller‐Tidow, C. (2013) · Leukemia · doi:10.1038/leu.2013.242 · Cited by 127
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 130
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 128
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 127
Self-citationThe Role of IDH Mutations in Acute Myeloid Leukemia
Bravo, G. M., & Dinardo, C. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0523 · Cited by 128
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
Izquierdo-Garcia, J. L., Viswanath, P., Eriksson, P., Cai, L., Radoul, M., Chaumeil, M. M., Blough, M., Luchman, H. A., Weiss, S., Cairncross, J. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0840 · Cited by 123
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00427 · Cited by 125
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Self-citationAlterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Self-citationvan den Bent, M. J., Erdem‐Eraslan, L., Idbaïh, A., de Rooi, J., Eilers, P. H. C., Spliet, W. G. M., den Dunnen, W. F. A., Tijssen, C. C., Wesseling, P., Smitt, P. A. E. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1157 · Cited by 120
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 125
Epigenetic modulation of metabolism in glioblastoma
Dong, Z., & Cui, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.002 · Cited by 119
Optical/electrochemical methods for detecting mitochondrial energy metabolism
Ji, W., Tang, X. X., Du, W., Lu, Y., Wang, N., Wu, Q., Wei, W., Liu, J., Yu, H., Ma, B., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01610a · Cited by 124
Self-citationAn Epigenetic Role of Mitochondria in Cancer
Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 131
Self-citationReprogramming the epigenome with vitamin C
Lee Chong, T., Ahearn, E. L., & Cimmino, L. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00128 · Cited by 120
Cellular metabolism of myeloid cells in sepsis
Arts, R. J. W., Gresnigt, M. S., Joosten, L. A. B., & Netea, M. G. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.4mr0216-066r · Cited by 126
Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets
Mishra, S. K., Millman, S. E., & Zhang, L. (2022) · Blood · doi:10.1182/blood.2022018092 · Cited by 127
Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., & Gu, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068782 · Cited by 127
Dynamic DNA methylation of matrix metalloproteinase-9 in the development of diabetic retinopathy
Kowluru, R. A., Shan, Y., & Mishra, M. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.78 · Cited by 120
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 121
Playing TETris with DNA modifications
Delatte, B., Deplus, R., & Fuks, F. (2014) · The EMBO Journal · doi:10.15252/embj.201488290 · Cited by 118
Müller, T., Gessi, M., Waha, A., Isselstein, L., Luxen, D., Freihoff, D., Freihoff, J., Becker, A. J., Simon, M., Hammes, J., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.017 · Cited by 116
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 119
Zhang, H., Badur, M. G., Divakaruni, A. S., Parker, S. J., Jäger, C., Hiller, K., Murphy, A. N., & Metallo, C. M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.102 · Cited by 118
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Karpel‐Massler, G., Ishida, C. T., Bianchetti, E., Zhang, Y., Shu, C., Tsujiuchi, T., Banu, M. A., Garcia, F., Roth, K. A., Bruce, J. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00984-9 · Cited by 121
Self-citationModrek, A. S., Golub, D., Khan, T. A., Bready, D., Prado, J., Bowman, C., Deng, J., Zhang, G., Rocha, P. P., Raviram, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.009 · Cited by 118
The role of 5-hydroxymethylcytosine in human cancer
Pfeifer, G. P., Xiong, W., Hahn, M. A., & Jin, S. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1896-7 · Cited by 118
Molecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 124
Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma
Jo, V. Y., Chau, N. G., Hornick, J. L., Krane, J. F., & Sholl, L. M. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.239 · Cited by 116
Almeida, L., Dhillon-LaBrooy, A., Carriche, G. M., Berod, L., & Sparwasser, T. D. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.033 · Cited by 117
Mutant IDH is sufficient to initiate enchondromatosis in mice
Hirata, M., Sasaki, M., Cairns, R. A., Inoue, S., Puviindran, V., Li, W. Y., Snow, B. E., Jones, L. D., Wei, Q., Sato, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424400112 · Cited by 115
Self-citationTéllez-Plaza, M., Tang, W., Shang, Y., Umans, J. G., Francesconi, K. A., Goessler, W., Ledesma, M., León, M., Laclaustra, M., Pollak, J., et al. (2014) · Environmental Health Perspectives · doi:10.1289/ehp.1306674 · Cited by 120
Metabostemness: A New Cancer Hallmark
Menéndez, J. A., & Alarcón, T. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00262 · Cited by 116
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 116
Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024
Du, Y., Bian, Y., Baecker, D., Dhawan, G., Semghouli, A., Kiss, L., Zhang, W., Sorochinsky, A. E., Soloshonok, V. A., & Han, J. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202500662 · Cited by 124
Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
Mutant IDH1 Promotes Glioma Formation In Vivo
Philip, B., Yu, D. X., Silvis, M. R., Shin, C., Robinson, J. P., Robinson, G. L., Welker, A., Angel, S. N., Tripp, S. R., Sonnen, J. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.133 · Cited by 112
Genotoxic therapy and resistance mechanism in gliomas
Lang, F., Liu, Y., Chou, F.-J., & Yang, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107922 · Cited by 116
Self-citationTET2 as an epigenetic master regulator for normal and malignant hematopoiesis
Nakajima, H., & Kunimoto, H. (2014) · Cancer Science · doi:10.1111/cas.12484 · Cited by 117
Targeting Cancer Metabolism - Revisiting the Warburg Effects
Tran, Q., Lee, H., Park, J., Kim, S., & Park, J. (2016) · Toxicological Research · doi:10.5487/tr.2016.32.3.177 · Cited by 116
Self-citationIntegrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma
Goeppert, B. F., Tóth, R., Singer, S., Albrecht, T., Lipka, D. B., Lutsik, P., Brocks, D., Baehr, M., Muecke, O., Assenov, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30493 · Cited by 112
The role of histone demethylases in cancer therapy
Hoffmann, I., Roatsch, M., Schmitt, M., Carlino, L., Pippel, M., Sippl, W., & Jung, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.004 · Cited by 113
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1274 · Cited by 108
Porporato, P. E., Payen, V. L., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2100-2 · Cited by 115
Shih, A. H., Meydan, C., SHANK, K. R., Garrett-Bakelman, F. E., Ward, P. S., Intlekofer, A. M., Nazir, A., Stein, E. M., Knapp, K. M., Glass, J. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1049 · Cited by 113
Alterations in the placental methylome with maternal obesity and evidence for metabolic regulation
Mitsuya, K., Parker, A. N., Liu, L., Ruan, J., Vissers, M. C. M., & Myatt, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186115 · Cited by 113
Self-citation
Metadata
- Authors
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L.-X., Jiang, W.-Q., Liu, J., Zhang, J.-Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.-H., Lei, Q.-Y., Guan, K.-L., Zhao, S.-M., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3229304
- OpenAlex
- W2131860315
- Cited by
- 2,875
- References
- 55
- Citations by year
- 2026: 165 · 2025: 168 · 2024: 192 · 2023: 182 · 2022: 183 · 2021: 270 · 2020: 214 · 2019: 191 · 2018: 195 · 2017: 183 · 2016: 196 · 2015: 180 · 2014: 183 · 2013: 157 · 2012: 137
- FWCI
- 90.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 928 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (11079016, 30600112, 30871255, 30971485/C0706)
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China (2011CB910600, 2011CB965300)
- Project 985
- Major State Basic Research Development Program of China (2009CB918401, 2009CB918600)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate-dependent dioxygenase, IDH1 mutation, IDH2 mutation, histone demethylase, 5-hydroxymethylcytosine, competitive inhibition, glioma, acute myeloid leukemia, DNA methylation, histone methylation, active site
- MeSH terms
- Animals, Binding, Competitive, Cytosine, DNA-Binding Proteins, Glioma, Glutarates, Histones, Humans, Mixed Function Oxygenases, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Oxalates, Oxidoreductases, N-Demethylating, Procollagen-Proline Dioxygenase, Proto-Oncogene Proteins, Gene Expression, Caenorhabditis elegans, Homeodomain Proteins, Amino Acid Substitution, Catalytic Domain, Caenorhabditis elegans Proteins, Endostatins, 5-Methylcytosine, F-Box Proteins, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Histone Demethylases, Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
